nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2003-7-1-13-19nefr-985Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESГИПЕРГОМОЦИСТЕИНЕМИЯ И СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ У БОЛЬНЫХ НА ХРОНИЧЕСКОМ ДИАЛИЗЕHYPERHOMOCYSTEINEMIA AND CARDIOVASCULAR DISEASES IN PATIENTS ON MAINTAINING DIALYSISДобронравовВ. А.DobronravovV. A.ЖлобаА. А.ZhlobaA. A.ГолубевР. В.GolubevR. V.Научно-исследовательский институт нефрологии и кафедра биохимии, Санкт-Петербургский государственный медицинский Университет им. акад. И.П.ПавловаRussian Federation200310012003711319Copyright © Добронравов В.А., Жлоба А.А., Голубев Р.В., 20032003Добронравов В.А., Жлоба А.А., Голубев Р.В.Dobronravov V.A., Zhloba A.A., Golubev R.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/985
Гипергомоцистеинемия и сердечно-сосудистые заболевания у больных на хроническом диализе.
Hyperhomocysteinemia and cardiovascular diseases in patients on maintaining dialysis.
гомоцистеингипергомоцистеинемиядиализсердечно-сосудистые заболеванияфолиевая кислотаhomocysteinhyperhomocysteinemiadialysiscardiovascular diseasesfolic acidReferencesBostom AG, Lathrop L Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52 (1): 10-20Bostom AG, Lathrop L Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52 (1): 10-20Buccianti G, Raselli S, Baragetti I et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002; 17(5): 857-864Buccianti G, Raselli S, Baragetti I et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002; 17(5): 857-864van Güldener С, Stam F, Stehouver CDA Homocysteine metabolism in renal failure. Kidneylnt 2001; 59 [Suppl. 78]: 234-237van Güldener С, Stam F, Stehouver CDA Homocysteine metabolism in renal failure. Kidneylnt 2001; 59 [Suppl. 78]: 234-237Guttormsen AB, Ueland PM, Svarstad E, Refsum H Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52 (2): 495-502Guttormsen AB, Ueland PM, Svarstad E, Refsum H Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52 (2): 495-502Khan IN, Protesi A, Yiannakis E et al. Homocysteinaemia in patients receiving renal replacement therapy (RRT): relationship with dietary nutrient intake and mode of RRT. Nephrol Dial Transplant 1997; 12 (11): 2470-2471Khan IN, Protesi A, Yiannakis E et al. Homocysteinaemia in patients receiving renal replacement therapy (RRT): relationship with dietary nutrient intake and mode of RRT. Nephrol Dial Transplant 1997; 12 (11): 2470-2471Fowler B The folate cycle and disease in humans. Kidney Int 2001; 59 [Suppl. 78]: 221-229Fowler B The folate cycle and disease in humans. Kidney Int 2001; 59 [Suppl. 78]: 221-229van Güldener С, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidneylnt 1999; 56(3): 1064-1071van Güldener С, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidneylnt 1999; 56(3): 1064-1071Loehrer FMT, Angst CP, Brunner FP et al. Evidence for disturbed S-adenosylmethionine:S-adenosyIhomocysteine ratio in patients with ESRF: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998; 13 (3): 656-661Loehrer FMT, Angst CP, Brunner FP et al. Evidence for disturbed S-adenosylmethionine:S-adenosyIhomocysteine ratio in patients with ESRF: a cause for disturbed methylation reactions? Nephrol Dial Transplant 1998; 13 (3): 656-661McCuIIy K S Homocysteine, folate,vitamin B6, and cardiovascular disease. JAMA 1998; 279 (5): 392-393McCuIIy K S Homocysteine, folate,vitamin B6, and cardiovascular disease. JAMA 1998; 279 (5): 392-393Perna AF, Ingrosso D, De Santo NG et al. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidneylnt 1995; 47(1): 247-253Perna AF, Ingrosso D, De Santo NG et al. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidneylnt 1995; 47(1): 247-253Ross R The pathogenesis of atherosclerosis. In: Braunwald E (ed.) Heart disease. A textbook of cardiovascular medicine. 4th ed. Philadelphia: W. B. Saunders Company; 1992: 1106-1125Ross R The pathogenesis of atherosclerosis. In: Braunwald E (ed.) Heart disease. A textbook of cardiovascular medicine. 4th ed. Philadelphia: W. B. Saunders Company; 1992: 1106-1125Goldsmith DJA1 Covic A Coronary artery disease in uremia: etiology, diagnosis and therapy. Kidney Int 2001; 60 (6): 2059-2075Goldsmith DJA1 Covic A Coronary artery disease in uremia: etiology, diagnosis and therapy. Kidney Int 2001; 60 (6): 2059-2075Perna AF, Ingrosso D, Castaldo P et al. Homocysteine and transmethylations in uremia. Kidney Int 2001; 59 [Suppl. 78]: 230-233Perna AF, Ingrosso D, Castaldo P et al. Homocysteine and transmethylations in uremia. Kidney Int 2001; 59 [Suppl. 78]: 230-233Boushey CJ, Beresford SAA1 Omenn GS, MotuIsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274 (13): 1049-1057Boushey CJ, Beresford SAA1 Omenn GS, MotuIsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274 (13): 1049-1057Stangl V1 Baumann G, Stangl K Coronary atherogenic risk factors in women. Eu rHeart J 2002; 23 (22): 1738-1752Stangl V1 Baumann G, Stangl K Coronary atherogenic risk factors in women. Eu rHeart J 2002; 23 (22): 1738-1752Nygard 0, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274 (16): 1526-1533Nygard 0, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274 (16): 1526-1533O CaIIaghan P, Meleady R, Fitzgerald T, Graham I Smoking and plasma homocysteine. Eur Heart J 2002; 23 (20): 1580-1586O CaIIaghan P, Meleady R, Fitzgerald T, Graham I Smoking and plasma homocysteine. Eur Heart J 2002; 23 (20): 1580-1586Wilcken DEL Homocysteine, smoking and vascular disease. Eur Heart J 2002; 23 (20): 1559-1560Wilcken DEL Homocysteine, smoking and vascular disease. Eur Heart J 2002; 23 (20): 1559-1560Kunz K, Petitjean P, Lisri M et al. Cardiovascular morbidity and endothelial dysfunction in chronic HD patients: is homocysteine the missing link? Nephrol Dial Transplant 1999; 14(8): 1934-1942Kunz K, Petitjean P, Lisri M et al. Cardiovascular morbidity and endothelial dysfunction in chronic HD patients: is homocysteine the missing link? Nephrol Dial Transplant 1999; 14(8): 1934-1942Коношкова РЛ Ишемические изменения миокарда у больных с хронической почечной недостаточностью, получающих терапию гемодиализом. Нефрология 2000; 3: 18-26Коношкова РЛ Ишемические изменения миокарда у больных с хронической почечной недостаточностью, получающих терапию гемодиализом. Нефрология 2000; 3: 18-26Rosenthal AF, Ginsberg MJ, Crawford JF Homocysteine and heart disease in dialysis patients. Dial Transpl 1998; 27 (10): 627-630Rosenthal AF, Ginsberg MJ, Crawford JF Homocysteine and heart disease in dialysis patients. Dial Transpl 1998; 27 (10): 627-630Hagen W, Fodinger M, Heinz G et al. Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. Kidney Int 2001; 59 [Suppl 78]: 253-257Hagen W, Fodinger M, Heinz G et al. Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. Kidney Int 2001; 59 [Suppl 78]: 253-257DuclouxD, RuedinC, GibeyRetaI. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant 1998; 13 (11): 2890-2893DuclouxD, RuedinC, GibeyRetaI. Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant 1998; 13 (11): 2890-2893Chauveau P, Chadefaux B1 Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43 [Suppl 41]: 72-77Chauveau P, Chadefaux B1 Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43 [Suppl 41]: 72-77Bergstrom J, Furst P Uraemic toxins. In: Drukker W1 Parsons FM, Maher JF (eds.) Replacement of renal function by dialysis. 2nd ed. Boston: Martinus Nijhoff publishers; 1984: 354-391Bergstrom J, Furst P Uraemic toxins. In: Drukker W1 Parsons FM, Maher JF (eds.) Replacement of renal function by dialysis. 2nd ed. Boston: Martinus Nijhoff publishers; 1984: 354-391Libetta C, Villa G, Pirrelli S et al. Homocysteine plasma levels correlate with intimal carotid artery thickness in hemodialysis patients. Nephrol Dial Transplant 2001; 16 (12): 2444-2445Libetta C, Villa G, Pirrelli S et al. Homocysteine plasma levels correlate with intimal carotid artery thickness in hemodialysis patients. Nephrol Dial Transplant 2001; 16 (12): 2444-2445Sirrs S, Duncan L, Djurdjev O et al. Homocysteine and vascular access complications in hemodialysis patients: insights into a complex metabolic relationships. Nephrol Dial Transplant 1999; 14 (3): 738-743Sirrs S, Duncan L, Djurdjev O et al. Homocysteine and vascular access complications in hemodialysis patients: insights into a complex metabolic relationships. Nephrol Dial Transplant 1999; 14 (3): 738-743Bostom AG, Shemin D1 Gohn RY et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int 2001; 59 [Suppl 78]: 246-252Bostom AG, Shemin D1 Gohn RY et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int 2001; 59 [Suppl 78]: 246-252Stein G, Muller A, Busch M et al. Homocysteine, its metabolites, and В-group vitamins in renal transplant patients. Kidneylnt 2001; 59 [Suppl 78]: 262-265Stein G, Muller A, Busch M et al. Homocysteine, its metabolites, and В-group vitamins in renal transplant patients. Kidneylnt 2001; 59 [Suppl 78]: 262-265Wrone EM, Zehnder JL1 Hornberger JM et al. An MTHFR variant, homocysteine and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60 (3): 1106-1114Wrone EM, Zehnder JL1 Hornberger JM et al. An MTHFR variant, homocysteine and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60 (3): 1106-1114Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 C to T) in the methyltetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52 (2): 517-523Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 C to T) in the methyltetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52 (2): 517-523van Güldener С, Donker AJM1 Jakobs C et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54(1): 166-169van Güldener С, Donker AJM1 Jakobs C et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54(1): 166-169Ignnatescu MC, Fodinger M, Kletzmayr J et al. Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells? Kidneyint 2001; 59 [Suppl 78]: 258-261Ignnatescu MC, Fodinger M, Kletzmayr J et al. Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells? Kidneyint 2001; 59 [Suppl 78]: 258-261Bostom AG, Shemin D, Lapane KL et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidneylnt 1996; 49 (1): 147-1521Bostom AG, Shemin D, Lapane KL et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidneylnt 1996; 49 (1): 147-1521Ducloux D, Aboubakr A, Motte G et al. Hyperhomocysteinaemia therapy in hemodialysis patients: folinic vs folic acid in combination with vitamins B6 and Bt2 Nephrol Dial Transplant 2002; 17 (5): 865-870Ducloux D, Aboubakr A, Motte G et al. Hyperhomocysteinaemia therapy in hemodialysis patients: folinic vs folic acid in combination with vitamins B6 and Bt2 Nephrol Dial Transplant 2002; 17 (5): 865-870van Güldener С, Janssen MJFM, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13 (1): 106-112van Güldener С, Janssen MJFM, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13 (1): 106-112Rimm EB1 Willett WC1 Hu FB et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279 (5): 359-365Rimm EB1 Willett WC1 Hu FB et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279 (5): 359-365Fodinger M1 Wagner OF1 Horl WH1 Sunder-Plassmann G Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001; 59 [Suppl 78]: 238-242Fodinger M1 Wagner OF1 Horl WH1 Sunder-Plassmann G Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001; 59 [Suppl 78]: 238-242Liangos 0, Kreutz R, Beige J et al. Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. Nephrol Dial Transplant 1998; 13 (9): 2351-2354Liangos 0, Kreutz R, Beige J et al. Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. Nephrol Dial Transplant 1998; 13 (9): 2351-2354Jacques PF; Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93(1): 7-9Jacques PF; Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93(1): 7-9Massy ZA Reversal of hyperhomocyst(e)inaemia in chronic renal failure -is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14 (12): 2810-2812Massy ZA Reversal of hyperhomocyst(e)inaemia in chronic renal failure -is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14 (12): 2810-2812Bayes B, Pastor MC, Bonal J et al. Homocysteine and lipid peroxidation in hemodialysis: role of folinic acid and vitamin E. Nephrol Dial Transplant 2001; 16 (11): 2172-2175Bayes B, Pastor MC, Bonal J et al. Homocysteine and lipid peroxidation in hemodialysis: role of folinic acid and vitamin E. Nephrol Dial Transplant 2001; 16 (11): 2172-2175Mezzano D, Pais E, Aranda E et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60 (5): 1844-1851Mezzano D, Pais E, Aranda E et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60 (5): 1844-1851Massy ZA, Ceballos I, Chadefaux-Vekemens B et al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney Int 2001; 59 [Suppl 78]: 243-245Massy ZA, Ceballos I, Chadefaux-Vekemens B et al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney Int 2001; 59 [Suppl 78]: 243-245Arnadottir H, Berg A-L, Hegbrat J et al. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14 (1): 142-146Arnadottir H, Berg A-L, Hegbrat J et al. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14 (1): 142-146Churchill DN Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients. Kidney Int 1993; 43 [Suppl 41]: 16-22Churchill DN Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients. Kidney Int 1993; 43 [Suppl 41]: 16-22Lameire N1VanhoIder RC, van Loo A et al. Cardiovascular diseases in peritoneal dialysis patients: The size of the problem. Kidneylnt 1996; 50 [Suppl 56]: 28-36Lameire N1VanhoIder RC, van Loo A et al. Cardiovascular diseases in peritoneal dialysis patients: The size of the problem. Kidneylnt 1996; 50 [Suppl 56]: 28-36Vychytil A, Fodinger M, Wolfl G et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney/r>M998; 53 (6): 1775-1782Vychytil A, Fodinger M, Wolfl G et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney/r>M998; 53 (6): 1775-1782Brulez HFH, van Güldener С, Donker AJM, ter Wee PM The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 1999; 14 (1): 154-159Brulez HFH, van Güldener С, Donker AJM, ter Wee PM The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 1999; 14 (1): 154-159
The authors declare that there are no conflicts of interest present.